Oritel-M 40mg/50mg Tablet is a combination antihypertensive medication containing Telmisartan 40mg and Metoprolol Succinate 50mg. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, resulting in lowered blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that decreases heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac function. This combination is indicated for the management of hypertension, providing complementary mechanisms to achieve optimal blood pressure control and reduce the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. Oritel-M is particularly beneficial in patients requiring dual therapy for hypertension who may also have concomitant conditions like ischemic heart disease or left ventricular dysfunction. The medication should be administered as prescribed by a healthcare professional, with regular monitoring of blood pressure, heart rate, and renal function. Caution is advised in patients with bradycardia, heart block, severe hepatic or renal impairment, and in those with a history of hypersensitivity to either component. Adverse effects may include dizziness, fatigue, hypotension, and gastrointestinal disturbances.